Oleuropein enhances the non-amyloidogenic pathway by facilitating amyloid precursor protein (APP) clearance, inhibiting amyloid-beta (Aβ) aggregation, and disrupting preformed Aβ fibrils, positioning it as a promising therapeutic agent for Alzheimer’s disease [36,37,38]. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.